GSK plc Sponsored ADR logo

GSK plc Sponsored ADR (GSK)

Market Closed
15 Jun, 20:00
NYSE NYSE
$
52. 23
-0.81
-1.5272%
$
106.31B Market Cap
13.56 P/E Ratio
0.39% Div Yield
3.24M Volume
1.95 Eps
$ 53.04
Previous Close
Add Transaction
Day Range
52.17 53.2
Year Range
35.45 61.7
Want to track GSK and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!
UK approves combination therapies of GSK's blood cancer drug Blenrep

UK approves combination therapies of GSK's blood cancer drug Blenrep

GSK said on Thursday two combination therapies with its cancer drug, Blenrep, have received approval from British authorities for the treatment of a type of blood cancer in adults who had received at least one other therapy previously.

Reuters | 1 year ago
Here's Why GSK (GSK) is a Strong Value Stock

Here's Why GSK (GSK) is a Strong Value Stock

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

Zacks | 1 year ago
GSK's Pentavalent Meningococcal Jab Recommended for Use by ACIP

GSK's Pentavalent Meningococcal Jab Recommended for Use by ACIP

The U.S. CDC's Advisory Committee recommends the use of GSK's pentavalent Penmenvy vaccine as part of the adolescent meningococcal vaccination schedule.

Zacks | 1 year ago
GSK & PFE's RSV Vaccines Recommended for Use in Adults Aged 50-59

GSK & PFE's RSV Vaccines Recommended for Use in Adults Aged 50-59

The U.S. CDC's Advisory Committee recommends the use of GSK and Pfizer's RSV vaccines in adults aged 50-59 who are at high risk of severe RSV disease.

Zacks | 1 year ago
GSK in breach for misleading prescribing information on Omjjara, industry body says

GSK in breach for misleading prescribing information on Omjjara, industry body says

British pharmaceutical giant GSK has not met required ethical and regulatory standards in its marketing and prescription information for its Omjjara drug, an industry self-regulatory body said on Tuesday.

Reuters | 1 year ago
Will Glaxo (GSK) Beat Estimates Again in Its Next Earnings Report?

Will Glaxo (GSK) Beat Estimates Again in Its Next Earnings Report?

Glaxo (GSK) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

Zacks | 1 year ago
Why GSK (GSK) is a Top Value Stock for the Long-Term

Why GSK (GSK) is a Top Value Stock for the Long-Term

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

Zacks | 1 year ago
GSK Secures FDA Nod for Oral Antibiotic to Treat Urinary Tract Infection

GSK Secures FDA Nod for Oral Antibiotic to Treat Urinary Tract Infection

The FDA approval is based on late-stage data, which shows that GSK's Blujepa is at least as effective as a leading standard treatment for uncomplicated UTIs.

Zacks | 1 year ago
US FDA approves GSK's urinary tract infection drug

US FDA approves GSK's urinary tract infection drug

The U.S. Food and Drug Administration on Tuesday approved GSK's drug for a common type of urinary tract infection (UTI) in women and adolescent girls, one of five new approvals the British drugmaker has been expecting this year.

Reuters | 1 year ago
GSK studying if best-selling shingles vaccine lowers dementia risk

GSK studying if best-selling shingles vaccine lowers dementia risk

GSK said on Tuesday that it is studying a group of more than a million older adults in the UK to examine whether its best-selling shingles vaccine lowers the risk of dementia.

Reuters | 1 year ago
EMA Accepts GSK's Filing for Expanded Use of Nucala in COPD

EMA Accepts GSK's Filing for Expanded Use of Nucala in COPD

The European Medicines Agency accepts GSK's regulatory filing for expanded use of Nucala to treat COPD for review.

Zacks | 1 year ago
GSK says European regulator reviewing expanded use of asthma drug Nucala

GSK says European regulator reviewing expanded use of asthma drug Nucala

GSK on Monday said that the European Medicines Agency has agreed to review a request to approve the British drugmaker's asthama drug Nucala as an additional treatment for chronic obstructive pulmonary disease (COPD) with an eosinophilic phenotype.

Reuters | 1 year ago
Loading...
Load More